Icecure Medical Ltd. (ICCM)
NASDAQ:ICCM
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$0.28 - $1.40
Previous CloseN/A
Volume318.06K
Average Volume (3M)686.35K
Market Cap
$23.18M
Enterprise Value$15.69M
Total Cash (Recent Filing)$8.90M
Total Debt (Recent Filing)$217.00K
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Jun 03, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,693,054
10 Day Avg. Volume812,942
30 Day Avg. Volume686,345
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.29
Price to Sales (P/S)11.48
P/FCF Ratio-2.66
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue4.64
Enterprise Value/Gross Profit12.79
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$3.00Price Target Upside248.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$5.08M
Bulls Say, Bears Say
Bulls Say
Clinical Adoption And Commercial FootprintActivation of post-market study sites that also operate as commercial centers can increase physician access to ProSense, supporting additional device placements and consumable sales.
Guideline Inclusion And ReimbursementInclusion of cryoablation in the American Society of Breast Surgeons' guidance, together with eligibility for reimbursement under an established procedural code, improves the economic case for facilities to offer the procedure.
Regulatory ProgressRegulatory submission to Health Canada to expand ProSense approval for early-stage, low-risk breast cancer in older patients may broaden the product's approved indications and open a new patient market.
Bears Say
Cash Runway And Financing NeedDeclining cash on hand and continued cash burn increase the likelihood that the company will need to secure additional capital to sustain operations.
Revenue VolatilityDistributor ordering patterns can cause quarter-to-quarter swings in reported revenue, making near-term sales performance more unpredictable.
Valuation RiskShares trading at a substantial premium to peers heighten downside risk if market adoption of ProSense falls short of expectations.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $0.28 and its highest was $1.40 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $23.18M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 49 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on Mar 17, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -0.05.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 68,693,054 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -8.904%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Icecure Medical Ltd.
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
ICCM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear positive momentum driven by the October 2025 FDA clearance, a major professional society recommendation (ASBRS), record 2025 revenue ($3.4M) and expanding global and U.S. commercial interest with a growing pipeline and planned expansion of the U.S. sales force. Near-term catalysts include the PMS rollout, transitional pass-through payment and pursuit of CPT1 physician reimbursement, all of which could materially accelerate adoption if achieved. Offsetting risks are execution and timing uncertainties around PMS site conversion, broader reimbursement finalization, regional regulatory approvals (Health Canada, Japan) and limited disclosed detail on production ramp. Overall, the highlights (regulatory validation, society endorsement, revenue records, clinical/publication momentum and expanding pipeline) substantially outweigh the operational and timing lowlights.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$3.00
▲(248.84% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.11% Other Institutional Investors
99.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---